The combination preparation fluticasone/salmeterol is a formulation containing fluticasone propionate and salmeterol xinafoate, used in the management of asthma and chronic obstructive pulmonary disease (COPD). It is marketed by GlaxoSmithKline under various trade names including Advair (in the US and Canada), Seretide (Brazil, India, Australia, Colombia, EU, Russia, México, New Zealand, South Africa, South Korea, Turkey, UK, Estonia), Viani (Germany), Adoair (Japan) and Foxair (South Africa).

Property Value
dbo:abstract
  • The combination preparation fluticasone/salmeterol is a formulation containing fluticasone propionate and salmeterol xinafoate, used in the management of asthma and chronic obstructive pulmonary disease (COPD). It is marketed by GlaxoSmithKline under various trade names including Advair (in the US and Canada), Seretide (Brazil, India, Australia, Colombia, EU, Russia, México, New Zealand, South Africa, South Korea, Turkey, UK, Estonia), Viani (Germany), Adoair (Japan) and Foxair (South Africa). In India it is marketed by Intas under the trade name Quikhale SF. Annual worldwide sales were approximately US$7 billion in 2009. Patent protection in the US expired in 2010, and European patent protection expired in 2013. However, the availability of a generic form of Advair in the United States may be significantly delayed because the Food and Drug Administration has not determined a standard for the bioequivalence of inhaled steroids in multi-dose inhalers or dry powder inhalers.Fluticasone, a corticosteroid, is the anti-inflammatory component of the combination, while salmeterol treats constriction of the airways. Together, they help prevent symptoms of coughing, wheezing and shortness of breath. (en)
  • The combination preparation fluticasone/salmeterol is a formulation containing fluticasone propionate and salmeterol xinafoate, used in the management of asthma and chronic obstructive pulmonary disease (COPD). It is marketed by GlaxoSmithKline under various trade names including Advair (in the US and Canada), Seretide (Brazil, India, Australia, Colombia, EU, Russia, México, New Zealand, South Africa, South Korea, Turkey, UK, Estonia), Viani (Germany), Adoair (Japan) and Foxair (South Africa). In India it is marketed by Cipla under the trade name Seroflo. Annual worldwide sales were approximately US$7 billion in 2009. Patent protection in the US expired in 2010, and European patent protection expired in 2013. However, the availability of a generic form of Advair in the United States may be significantly delayed because the Food and Drug Administration has not determined a standard for the bioequivalence of inhaled steroids in multi-dose inhalers or dry powder inhalers.Fluticasone, a corticosteroid, is the anti-inflammatory component of the combination, while salmeterol treats constriction of the airways. Together, they help prevent symptoms of coughing, wheezing and shortness of breath. (en)
  • The combination preparation fluticasone/salmeterol is a formulation containing fluticasone propionate and salmeterol xinafoate, used in the management of asthma and chronic obstructive pulmonary disease (COPD). Patent protection in the US expired in 2010, and European patent protection expired in 2013. However, the availability of a generic form of Advair in the United States may be significantly delayed because the Food and Drug Administration has not determined a standard for the bioequivalence of inhaled steroids in multi-dose inhalers or dry powder inhalers.Fluticasone, a corticosteroid, is the anti-inflammatory component of the combination, while salmeterol, a long acting beta-adrenoceptor agonist (LABA), treats constriction of the airways. Together, they help prevent symptoms of coughing, wheezing and shortness of breath. (en)
dbo:thumbnail
dbo:wikiPageEditLink
dbo:wikiPageExtracted
  • 2017-09-30 01:17:19Z (xsd:date)
  • 2018-04-30 06:59:31Z (xsd:date)
  • 2019-02-26 10:05:16Z (xsd:date)
dbo:wikiPageHistoryLink
dbo:wikiPageID
  • 846109 (xsd:integer)
  • 60077452 (xsd:integer)
dbo:wikiPageLength
  • 53 (xsd:integer)
  • 5875 (xsd:integer)
dbo:wikiPageModified
  • 2018-02-08 09:24:26Z (xsd:date)
  • 2019-02-26 09:59:11Z (xsd:date)
dbo:wikiPageOutDegree
  • 1 (xsd:integer)
  • 18 (xsd:integer)
dbo:wikiPageRevisionID
  • 824597901 (xsd:integer)
  • 885161644 (xsd:integer)
dbo:wikiPageRevisionLink
dbp:atcPrefix
  • R03 (en)
dbp:atcSuffix
  • AK06 (en)
dbp:caption
  • Fluticasone propionate (en)
  • and salmeterol (en)
dbp:chemspiderid
  • 7987322 (xsd:integer)
dbp:class
dbp:component
  • Fluticasone propionate (en)
  • Salmeterol (en)
dbp:legalAu
  • S4 (en)
dbp:legalCa
  • Rx-only (en)
dbp:legalStatus
  • Rx-only (en)
dbp:legalUk
  • POM (en)
dbp:legalUs
  • Rx-only (en)
dbp:medlineplus
  • a699063 (en)
dbp:pregnancyAu
  • B3 (en)
dbp:pregnancyUs
  • C (en)
dbp:pubchem
  • 9811567 (xsd:integer)
dbp:routesOfAdministration
  • Inhalation (en)
dbp:smiles
  • O=C[C@]3[C@]2C.OCCCCCCNCCc2ccccCO (en)
dbp:stdinchikey
  • YYAZJTUGSQOFHG-RZFXJYHSSA-N (en)
dbp:tradename
  • Advair, Seretide (en)
dbp:type
  • combo (en)
dbp:verifiedrevid
  • 447411501 (xsd:integer)
dbp:width
  • 225 (xsd:integer)
dbp:wikiPageUsesTemplate
dct:subject
rdfs:comment
  • The combination preparation fluticasone/salmeterol is a formulation containing fluticasone propionate and salmeterol xinafoate, used in the management of asthma and chronic obstructive pulmonary disease (COPD). It is marketed by GlaxoSmithKline under various trade names including Advair (in the US and Canada), Seretide (Brazil, India, Australia, Colombia, EU, Russia, México, New Zealand, South Africa, South Korea, Turkey, UK, Estonia), Viani (Germany), Adoair (Japan) and Foxair (South Africa). (en)
  • The combination preparation fluticasone/salmeterol is a formulation containing fluticasone propionate and salmeterol xinafoate, used in the management of asthma and chronic obstructive pulmonary disease (COPD). Patent protection in the US expired in 2010, and European patent protection expired in 2013. (en)
rdfs:label
  • Fluticasone propionate/salmeterol (en)
foaf:depiction
foaf:isPrimaryTopicOf
owl:sameAs
is foaf:primaryTopic of